Investment in Vivici to accelerate protein transition

The investment is part of a Series A funding round of € 32.5 million, led by APG on behalf of pension fund ABP and Invest-NL, with participation from InnovationQuarter and existing shareholders dsm-firmenich and Fonterra. With the new financing, Vivici will scale up its commercial activities, introduce a second dairy protein ingredient to the market, and expand its production capacity.

Precision fermentation as a gamechanger in protein production

Vivici was founded in 2023 as a joint venture between dsm-firmenich and Fonterra, with the aim of commercialising precisely fermented dairy proteins for the B2B market. Precision fermentation combines traditional fermentation processes with modern biotechnology. The technology enables the production of high-quality proteins without the involvement of animals. This results in a significantly lower environmental impact compared to traditional dairy production.

"Fermentation technology plays an important role in the transition to a sustainable and CO₂-neutral food system," says Victor Meijer, senior investment manager at Invest-NL. "This innovative protein solution can fundamentally change food production. We are convinced that the team has the right expertise to successfully commercialise this technology."

Investing in a more sustainable food system

With this investment, Invest-NL contributes to accelerating the protein transition. By supporting innovative companies like Vivici, Invest-NL helps to scale sustainable technologies and speed up the transition to a future-proof, CO₂-neutral food system.